Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and beyond

Bastian Höchst, Percy A. Knolle

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

The immune system functions to defend the organism against infectious microorganisms but also against transformed cells. This key role of the immune system, in particular cancer-specific T cells, in eliminating cancer cells is compromised by various immune escape strategies employed by cancer cells and the cancer microenvironment. Here, we review the current knowledge about the immune escape mechanisms of cancer and the attempts to reconstitute cancer-specific immunity by using checkpoint inhibitors in head and neck squamous cell carcinoma. We discuss the different options of immune therapy based on a mechanistic understanding of the relevance of co-inhibitory signaling, regulatory T cells, and myeloid-derived suppressor cells. A thorough mechanistic understanding of cancer immune escape mechanisms and their presence in the individual patient is required in order to design effective multicomponent immune therapies in the future.

Original languageEnglish
Pages (from-to)24-33
Number of pages10
JournalORL
Volume79
Issue number1-2
DOIs
StatePublished - 1 Feb 2017
Externally publishedYes

Keywords

  • CTLA-4
  • Checkpoint inhibition
  • Head and neck cancer
  • PD-1
  • Therapy

Fingerprint

Dive into the research topics of 'Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and beyond'. Together they form a unique fingerprint.

Cite this